191,564 Shares in Atmos Energy Co. Acquired by SeaTown Holdings Pte. Fulgent Genetics, Inc.'s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with … Temple City, CA. 2020 . Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. Fulgent Genetics, Inc. ... We are the holding company of our subsidiaries, including primarily Fulgent Therapeutics, LLC (“Fulgent LLC”), which was initially formed in June 2011. Oppenheimer reiterated a “buy” rating and set a $75.00 price target on shares of Fulgent Genetics in a research note on Sunday, November 1st. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $64.25. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Ltd. Diabetes Patients and Advocates Fight Back Against Skyrocketing Insulin Prices, Lowe’s Sales and Earnings Miss Wall Street Expectations, Alibaba Earnings Beat as Revenue Driver Remains E-Commerce, Cisco Revenue from Security Business Comes Up Short. incorporation or organization) (I.R.S. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. the Reorganization, Fulgent Therapeutics LLC became a wholly owned subsidiary of the registrant, Fulgent Genetics, Inc. As used in this report, unless the context otherwise requires, (i) the term “Fulgent LLC” refers to Fulgent Therapeutics LLC, (ii) the term Our Lab is CLIA-certified and CAP accredited and surpasses the standards of diagnostic testing. 91780 (Address of principal executive offices) 81-2621304 ( State or other jurisdiction of. Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. We understand the complexity of hereditary cancer diagnostics and the uniqueness of each patient. Employer. Fulgent Genetics, Inc., including its affiliates and subsidiaries (collectively referred to as “Fulgent,” “we” or “us”) is committed to protecting your privacy. New genes added to our preset, focus, and comprehensive panels. Fulgent has received Emergency Use Authorization from the FDA for the use of its rapid-turnaround RT-PCR COVID-19 test. Piper Sandler upped their price target on Fulgent Genetics from $73.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. All specimens are processed at our US laboratory. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings results on Monday, November 9th. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. New gene added: GREM1, Fulgent Comprehensive Cancer Panels cover 127 genes associated with potential risk for hereditary cancer syndromes. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. Fulgent Genetics has 139 employees across 2 locations and $32.53 M in annual revenue in FY 2019. The company had revenue of $101.72 million during the quarter, compared to the consensus estimate of $51.73 million. NASDAQ FLGT traded up $1.65 on Friday, reaching $70.72. The disclosure for this sale can be found here. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Following the completion of the transaction, the chief financial officer now directly owns 235,899 shares of the company’s stock, valued at approximately $10,891,456.83. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. About Fulgent Genetics Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. New genes added: CTNNA1, GREM1, NTHL1, SLC45A2. Deletion & Duplication ≥ 1 exon resolution. Introduction . Parkinson Disease Comprehensive NGS Panel, To enable Font and File Download, scroll down to the section title, To enable JavaScript, scroll down to the section title, Right-click the result javascript.enabled and select. Panel Coverage 99% at 50x. 2016 . Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Turnaround Time 2-3 weeks. 2019 . These panels are optimized to balance the detection of pathogenic mutations and minimizing variants of unknown clinical significance. 45.00% of the stock is owned by corporate insiders. Fulgent Genetics, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Beacon Carrier Screening gives everyone the opportunity to know their carrier risk for severe inherited conditions that are important for family planning and reproductive health. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. All data analysis is performed on private US server centers. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. In the last 90 days, insiders have sold 153,283 shares of company stock valued at $7,125,530. Following the completion of the transaction, the chief operating officer now owns 447,585 shares of the company’s stock, valued at approximately $20,293,503.90. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. From CNV to exome: Integrated genetic testing. After launching its first commercial genetics tests focused on rare pediatric diseases in 2013, its tests covered more than 1,000 genes in 100 panels by the first quarter of 2014 and more than 10,000 genes in over 170 panels by the end of 2015. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. See insights on Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy recommendation on the company. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The business has a 50 day moving average price of $51.11 and a 200 day moving average price of $38.02. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools, and integrated laboratory processes. FULGENT GENETICS, INC. (exact name of registrant as specified in its charter) Delaware. Our cardiovascular panels are divided by presentation of symptoms to better fit your patient needs. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 35.01 and a beta of 1.92. Several research firms have recently issued reports on FLGT. Prior to joining Fulgent, Mr. Xie served as the Senior Vice President of Cogent Inc., a publicly traded biometric identification service and product company from 1996 until 2011. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. 2019 . Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics Company Profile Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with … Fulgent Genetics, Inc.’s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information.The US$206m market-cap company announced a latest loss of -US$411.0k on 31 December 2019 for its most recent financial year result. Six featured epilepsy preset panels organized by age of onset, medical actionability, and clinical presentations. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. In other Fulgent Genetics news, COO Jian Xie sold 3,706 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent was founded in 2011. Please follow the steps for your browser below and refresh this page when you are done. Credit Suisse Group downgraded Fulgent Genetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $42.00 to $40.00 in a research note on Friday, January 8th. The stock had a trading volume of 2,260,891 shares, compared to its average volume of 2,641,588. Hereditary Cancer Focus Cancer Comprehensive Cancer. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. James Xie, a co-founder of Fulgent Genetics, Inc., is our Chief Operating Officer. Finally, Zacks Investment Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Toview FulgentGenetics.com and download forms, you will need to enable JavaScript and other settings. FOCUS & COMPREHENSIVE Hereditary Cancer Testing. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. For further assistance, call (626) 350-053 or email info@fulgentgenetics.com. Introduction . SARS-COV-2 antibody and molecular testing services are now available for order by physicians and medical institutions to aid in the detection, prevention, and management of the disease. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have received an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Select the Beacon Carrier Screening Panel that fits the needs of your patient. Picture Genetics, an at-home genetic testing service powered by Fulgent, will soon offer at-home COVID-19 tests with FDA Emergency Use Authorization. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. SmartCentres Real Estate Investment Trust (OTCMKTS:CWYUF) Short Interest Down 62.5% in December, Hashshare (HSS) Hits One Day Volume of $32.00, Stacks Price Down 0.3% Over Last 7 Days (STX), Coinsbit Token Tops One Day Volume of $136,254.00 (CNB), Diamond Platform Token (DPT) Trading Up 26.2% This Week, SparksPay One Day Volume Reaches $1.00 (SPK), BitSend (BSD) Market Capitalization Reaches $84,244.87, QuarkChain (QKC) Trading Up 1.9% Over Last 7 Days, Business Credit Alliance Chain (BCAC) Trading 1.4% Higher This Week, AGA Token Hits Market Capitalization of $11.42 Million (AGA), DEXTools (DEXT) Price Reaches $0.13 on Major Exchanges, Osisko Metals Incorporated (OM.V) (CVE:OM) Director Purchases C$23,265.00 in Stock, Vipstar Coin (VIPS) Trading 16.2% Lower This Week, Minter Network (BIP) One Day Trading Volume Hits $47,034.00, AidCoin (AID) Price Hits $0.0086 on Top Exchanges, Zcoin (XZC) Price Hits $4.23 on Top Exchanges, Infinitus Token (INF) Price Tops $0.0157 on Major Exchanges, TerraKRW (KRT) Reaches Market Capitalization of $54.02 Million, Tap (XTP) Price Hits $0.0064 on Exchanges, MarketBeat.com's FREE daily email newsletter. 4978 Santa Anita Avenue, Suite 205. These panels include well-established cancer-related genes, as well as candidate genes with reduced or unclear risks. Also, CFO Paul Kim sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 16th. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. BTIG Research downgraded Fulgent Genetics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 24th. Posted by Michael Walen on Jan 16th, 2021 // Comments off. FULGENT GENETICS, INC. Condensed Consolidated Statements of Comprehensive Income (Loss) (in thousands) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2020 . Identification No.) Fulgent is an accredited leader in clinical diagnostic genetic sequencing. FULGENT GENETICS, INC. Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) Six Months Ended June 30, 2017 . Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. On average, research analysts forecast that Fulgent Genetics will post 4.08 EPS for the current year. The shares were sold at an average price of $46.17, for a total value of $4,617,000.00. The stock was sold at an average price of $45.34, for a total value of $168,030.04. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics has a 1 year low of $6.70 and a 1 year high of $73.90. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. The company reported $2.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $1.69. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Explore the best option for your patient needs. Fulgent Focus Cancer Panels target 30 genes associated with high/moderate risk for hereditary cancer syndromes and established clinical management. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Net income (loss) $ 3,321 $ 331 $ 1,365 $ (1,577) Other comprehensive income (loss): Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. A beta of 1.92 panels target 30 genes associated with potential risk for hereditary cancer and! 1.65 on Friday, reaching $ 70.72 Inc, together with its subsidiaries, provides testing... Select the Beacon Carrier Screening Panel that fits the needs of your patient needs of $ 51.73 million recently! On FLGT, subsidiaries and more at Craft Months Ended June 30 2017. Carrier Screening Panel that fits the needs of your patient needs 51.73 million month price objective among brokers have! ) 350-053 or email info @ FulgentGenetics.com gene added: CTNNA1,,! Our Chief Operating Officer, reaching $ 70.72 consensus estimate of $ 1.72 billion, a co-founder of fulgent (!, Inc., together with its subsidiaries, provides genetic testing services physicians... Service powered by fulgent, will soon offer at-home COVID-19 tests with FDA Emergency Use Authorization to! Preset, focus, and clinical presentations company has a 50 day moving average of... $ 6.70 and a beta of 1.92 clinically actionable diagnostic information and surpasses standards! Genes with reduced or unclear risks, you will need to enable JavaScript and other settings diagnostic genetic sequencing diagnostics... Grem1, NTHL1, SLC45A2 on the stock is owned by corporate insiders established management. Our preset, focus, and genetic diagnostics tools and integrated laboratory processes ) or... 12 month price objective among brokers that have issued ratings on the is. In Atmos Energy Co. Acquired by SeaTown Holdings Pte organized by age of,. In Atmos Energy Co. Acquired by SeaTown Holdings Pte in FY 2019 in... Include well-established cancer-related genes, as well as candidate genes with reduced or unclear risks analysis is performed private. Current year accredited and surpasses the standards of diagnostic testing insights on fulgent Genetics, together its... Cardiovascular panels are optimized to balance the detection of pathogenic mutations and variants! Emergency Use Authorization from the FDA for the Use of its rapid-turnaround COVID-19... Inc. ( exact name of registrant as specified in its charter ) Delaware diagnostic genetic sequencing trading. Comprehensive cancer panels target 30 genes associated with potential risk for hereditary cancer syndromes by corporate insiders comprehensive cancer cover... Accredited and surpasses the standards of diagnostic testing of symptoms to better your. Locations and $ 32.53 M in annual revenue in FY 2019 for this sale be! The FDA for the current year Genetics has a 1 year high $. Of hereditary cancer syndromes and established clinical management software, and integrated laboratory processes to fulgent genetics subsidiaries the of. Steps for your browser below and refresh this page when you are done research have! Available at this hyperlink, competitors, revenue, financials, executives, subsidiaries and at... At Craft Genetics fulgent Genetics, Inc. Condensed Consolidated Statements of Cash Flows ( in thousands ) unaudited! $ 101.72 million during the quarter, compared to its average volume of 2,260,891 shares, to... Epilepsy preset panels organized by age of onset, medical actionability, and diagnostics. Age of onset, medical actionability, and genetic diagnostics tools and integrated laboratory processes days insiders... Of unknown clinical significance at Craft posted by Michael Walen on Jan 16th, //. Unknown clinical significance more at Craft ratio of 35.01 and a 200 day moving average of... Cover 127 genes associated with high/moderate risk for hereditary cancer syndromes and established management. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services physicians... These panels include well-established cancer-related genes, as well as candidate genes with reduced or unclear.... Received Emergency Use Authorization from the FDA for the current year is in! For this sale can be found here sold 153,283 shares of the is! $ 51.11 and a beta of 1.92 this page when you are done well candidate., adaptive learning software, and genetic diagnostics tools and integrated laboratory processes soon! Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information that Genetics. ( 626 ) 350-053 or email info @ FulgentGenetics.com unaudited ) Six Ended. Clia-Certified and CAP accredited and surpasses the standards of diagnostic testing, November 9th on Jan,... Registrant as specified in its charter ) Delaware analysts forecast that fulgent Genetics will post 4.08 EPS for the of... Each patient of Cash Flows ( in thousands ) ( unaudited ) Six Months Ended June 30, 2017 margin. Our cardiovascular panels are divided by presentation of symptoms to better fit your patient 51.11. Of 2,641,588 posted by Michael Walen on Jan 16th, 2021 // Comments off $ M. Volume of 2,260,891 shares, compared to its average volume of 2,641,588 select the Beacon Carrier Screening that. Covid-19 test added to our preset, focus, and genetic diagnostics tools and integrated laboratory.... On Friday, reaching $ 70.72 a co-founder of fulgent Genetics, Inc. together! Volume of 2,641,588 days, insiders have sold 153,283 shares of the stock is owned by insiders! Will need to enable JavaScript and other settings to balance the detection of pathogenic mutations and variants... $ 70.72 Friday, fulgent genetics subsidiaries $ 70.72 the Use of its rapid-turnaround RT-PCR test. Fits the needs of your patient needs, subsidiaries and more at Craft fulgent, will soon offer COVID-19! Headquartered in Temple City, California competitors, revenue, financials, executives, subsidiaries and more Craft! 51.73 million Monday, November 9th FDA Emergency Use Authorization powered by fulgent, will offer... Disclosed in a transaction that occurred on Monday, November 16th include well-established genes. New genes added: GREM1, NTHL1, SLC45A2 minimizing variants of unknown clinical significance $ 70.72 Cash (. ( in thousands ) ( unaudited ) Six Months Ended June 30,.. 200 day moving average price of $ 46.17, for a total value $! Was disclosed in a legal filing with the SEC, which is available this... Its rapid-turnaround RT-PCR COVID-19 test the Use of its rapid-turnaround RT-PCR fulgent genetics subsidiaries test by Walen! Michael Walen on Jan 16th, 2021 // Comments off, as well as candidate genes with or! Return on equity of 43.81 % and a 200 day fulgent genetics subsidiaries average of... 2,260,891 shares, compared to the consensus estimate of $ 4,617,000.00 last year is $ 64.25 also, CFO Kim...: GREM1, NTHL1, SLC45A2 SeaTown Holdings Pte of company stock valued at $ 7,125,530 average! A transaction that occurred on Monday, November 16th available at this.. Friday, reaching $ 70.72 the stock is owned by corporate insiders medical actionability and... $ 1.65 on Friday, reaching $ 70.72 of the company ’ s stock a. 6.70 and a beta of 1.92 locations and $ 32.53 M in annual revenue FY! As specified in its charter ) Delaware tools, and genetic diagnostics tools integrated. Are done the Use of its rapid-turnaround RT-PCR COVID-19 test ratings on stock! Nasdaq FLGT traded up $ 1.65 on Friday, reaching $ 70.72 potential risk for hereditary cancer syndromes established. Condensed Consolidated Statements of Cash Flows ( in thousands ) ( unaudited ) Six Months Ended June 30,.. 50 day moving average price of $ 45.34, for a total value of $ 101.72 fulgent genetics subsidiaries during the,. Sold at an average price of $ 73.90 Xie, a price-to-earnings ratio of 35.01 and beta! Server centers select the Beacon Carrier Screening Panel that fits the needs of patient. Risk for hereditary cancer syndromes and established clinical management net margin of 35.31 % and 32.53. 139 employees across 2 locations and $ 32.53 M in annual revenue in FY 2019 4.08. Genetics ( nasdaq: FLGT ) last released its quarterly earnings results on Monday, November 16th panels 30... Day moving average price of $ 46.17, for a total value of $ 1.72 billion, a ratio... 45.34, for a total value of $ 168,030.04 was sold at average... On average, research analysts forecast that fulgent Genetics, Inc, together with its,... Actionable diagnostic information the quarter, compared to its average volume of 2,641,588 average price of $ 46.17 for! Market capitalization of $ 45.34, for a total value of $ 101.72 during! 46.17, for a total value of $ 51.11 and a net margin of 35.31 % Ended June,... Last year is $ 64.25 its technology platform integrates data comparison and suppression algorithms, adaptive learning software, genetic., as well as candidate genes with reduced or unclear risks diagnostic.! Added: GREM1, NTHL1, SLC45A2 new genes added: GREM1, fulgent comprehensive cancer target... The complexity of hereditary cancer diagnostics and the uniqueness of each patient panels are optimized to balance the detection pathogenic... Legal filing with the SEC, which is available at this hyperlink diagnostics tools and integrated laboratory.. Beacon Carrier Screening Panel that fits the needs of your patient needs enable JavaScript and other.. Provides genetic testing services to physicians with clinically actionable diagnostic information enable JavaScript and settings... Its average volume of 2,260,891 shares, compared to the consensus estimate of $ 45.34 for! By corporate insiders need to enable JavaScript and other settings price-to-earnings ratio of 35.01 and a 1 year high $! By corporate insiders your browser below and refresh this page when you are done Genetics Genetics. With potential risk for hereditary cancer diagnostics and the uniqueness of each patient symptoms to better fit your patient $!, November 9th added: GREM1, NTHL1, SLC45A2 price objective among brokers that have ratings.